-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
SAB Biotherapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2021 to Q2 2025.
- SAB Biotherapeutics, Inc. Nonoperating Income (Expense) for the quarter ending June 30, 2025 was -$382K, a 113% decline year-over-year.
- SAB Biotherapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending June 30, 2025 was $4.77M, a 12.8% decline year-over-year.
- SAB Biotherapeutics, Inc. annual Nonoperating Income (Expense) for 2024 was $8.81M.
- SAB Biotherapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was -$4.12M, a 140% decline from 2022.
- SAB Biotherapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was $10.2M.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)